13F

AMRX AMNEAL PHARMACEUTICALS INC

2026Q1 · CUSIP 03168L105 · Sector: Healthcare & Biotech

Lit · Institutions accelerating in
Holders
313
Δ holders QoQ
+35
Breadth percentile
Top 8%
Whale holders
151
Δ whales
+10
Inst. holding value
$2.0B
New positions
78
Closed positions
43
Price momentum (1Q)
-21.5%
Put / Call
2/1

Breadth history (34 quarters)

2018Q3: Δ+2 · h=165 2018Q4: Δ+0 · h=165 2019Q1: Δ-5 · h=160 2019Q2: Δ-30 · h=130 2019Q3: Δ-5 · h=125 2019Q4: Δ+7 · h=132 2020Q1: Δ-5 · h=127 2020Q2: Δ+12 · h=139 2020Q3: Δ+2 · h=141 2020Q4: Δ-7 · h=134 2021Q1: Δ+26 · h=160 2021Q2: Δ+0 · h=160 2021Q3: Δ-6 · h=154 2021Q4: Δ+0 · h=154 2022Q1: Δ+14 · h=168 2022Q2: Δ-14 · h=154 2022Q3: Δ+4 · h=158 2022Q4: Δ-1 · h=157 2023Q1: Δ-12 · h=145 2023Q2: Δ-16 · h=129 2023Q3: Δ+15 · h=144 2023Q4: Δ+10 · h=154 2024Q1: Δ+23 · h=177 2024Q2: Δ+5 · h=182 2024Q3: Δ+2 · h=184 2024Q4: Δ+17 · h=201 2025Q1: Δ+39 · h=240 2025Q2: Δ+0 · h=240 2025Q3: Δ+11 · h=251 2025Q4: Δ+27 · h=278 2026Q1: Δ+35 · h=313 2018Q3: holders=165 2018Q4: holders=165 2019Q1: holders=160 2019Q2: holders=130 2019Q3: holders=125 2019Q4: holders=132 2020Q1: holders=127 2020Q2: holders=139 2020Q3: holders=141 2020Q4: holders=134 2021Q1: holders=160 2021Q2: holders=160 2021Q3: holders=154 2021Q4: holders=154 2022Q1: holders=168 2022Q2: holders=154 2022Q3: holders=158 2022Q4: holders=157 2023Q1: holders=145 2023Q2: holders=129 2023Q3: holders=144 2023Q4: holders=154 2024Q1: holders=177 2024Q2: holders=182 2024Q3: holders=184 2024Q4: holders=201 2025Q1: holders=240 2025Q2: holders=240 2025Q3: holders=251 2025Q4: holders=278 2026Q1: holders=313 -39 -19.5 +0 +19.5 +39 112221329 18Q319Q220Q120Q421Q322Q223Q123Q424Q325Q226Q1 Δ holders (bar) Holders (line)

Past Lit Events & Aftermath 7 lit events

Period Percentile Next-1Q return Next-2Q return
2026Q1 Top 8%
2025Q4 Top 19% -21.5%
2025Q1 Top 4% +24.4% +54.4%
2024Q1 Top 13% +19.5% +24.2%
2023Q3 Top 12% +32.3% +54.0%
2022Q1 Top 14% -30.3% -37.8%
2021Q1 Top 13% -14.0% -9.9%

Options Sentiment

Put holders
2
QoQ: +1
Call holders
1
QoQ: -1

See methodology →

Fundamentals

PE (TTM)
45.4
EPS (TTM)
$0.37
EPS YoY
Revenue (TTM)
$3.0B
Revenue YoY
+7.6%
Quarterly Revenue & EPS (4Y)
2022-06-30: $559M 2022-09-30: $546M 2022-12-31: $610M 2023-03-31: $558M 2023-06-30: $599M 2023-09-30: $620M 2023-12-31: $617M 2024-03-31: $659M 2024-06-30: $702M 2024-09-30: $702M 2024-12-31: $731M 2025-03-31: $695M 2025-06-30: $725M 2025-09-30: $785M 2025-12-31: $814M 2026-03-31: $723M 2024-03-31: EPS -0.30 2024-06-30: EPS 0.02 2024-09-30: EPS 0.00 2024-12-31: EPS -0.10 2025-03-31: EPS 0.04 2025-06-30: EPS 0.07 2025-09-30: EPS 0.01 2025-12-31: EPS 0.10 2026-03-31: EPS 0.19 0M 407M 814M $M -0.33 -0.06 0.21 20222023202420252026 Revenue EPS

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

P/E (TTM) over time
4Y median 582 2025-06-30: PE 9452025-09-30: PE 5822025-12-31: PE 67.42026-03-31: PE 32.2 29 511 992 20222023202420252026

P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden

As of 2026-03-31 · SEC filings (XBRL)